Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Salix Will Need To Dissolve Metozolv ODT Convenience Claims With Corrective Advertising Campaign; FDA Warning Letter Silent On REMS

Executive Summary

An effort by Salix Pharmaceuticals to tout advantages for its orally disintegrating metoclopramide product Metozolv ODT has ended with a need to run a corrective advertising campaign

You may also be interested in...



FDA Seeks More Data On Drug Exposure In Pregnancy, But Is Mining Insurance Records The Best Approach?

The Food and Drug Administration has asked outside investigators to begin tracking pregnant women's drug exposures and birth outcomes in hopes of generating better information for the pregnancy and lactation section of drug labels, although the agency is hedging its bets on the best way to compile the data

FDA Seeks More Data On Drug Exposure In Pregnancy, But Is Mining Insurance Records The Best Approach?

The Food and Drug Administration has asked outside investigators to begin tracking pregnant women's drug exposures and birth outcomes in hopes of generating better information for the pregnancy and lactation section of drug labels, although the agency is hedging its bets on the best way to compile the data

Xifaxan's Expanded Indication Comes With Additional Safety, Efficacy Trials

After drug gains approval to prevent recurrence of hepatic encephalopathy, Salix plans studies in patients with end-stage liver disease and in patients not taking lactulose.

Topics

UsernamePublicRestriction

Register

PS052099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel